Anti-MIP-3 beta/CCL19 antibody [EPR7044(2)]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

MIP-3 beta also known as CCL19 is a chemokine involved in immune responses. It weighs around 11 kDa and is encoded by the CCL19 gene. MIP-3 beta does its function by binding to its receptor CCR7 which is common in lymph nodes and other lymphoid tissues. It recruits and directs the migration of immune cells especially T cells and dendritic cells navigating them towards lymphoid tissues. This makes MIP-3 beta integral in initiating and modulating immune responses.

Biological function summary

MIP-3 beta helps direct cell trafficking within the lymphoid organs. It is not part of a complex but its interaction with the CCR7 receptor is essential for its biological activity. This binding plays a role in the development of secondary lymphoid organs and immune surveillance. Furthermore MIP-3 beta supports the homing of immune cells to appropriate locations impacting both innate and adaptive immune responses.

Pathways

MIP-3 beta is associated with the chemokine signaling pathway and the immune system pathway. Through these pathways it interacts with proteins like CCR7 and other chemokines that regulate leukocyte migration and activation. These pathways ensure local and systemic immune responses are efficiently orchestrated impacting inflammation and immune regulation.

Associated diseases and disorders

MIP-3 beta has connections to autoimmune diseases like rheumatoid arthritis and cancer. Its deregulation can result in abnormal immune surveillance contributing to the pathology of these conditions. MIP-3 beta regulates immune cell infiltration and any imbalance may also link it to other inflammatory disorders. Relations to proteins such as CCR7 in these conditions emphasize its role in disease pathogenesis and highlight its potential as a therapeutic target.